Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PrecipioPRPO -0.46%51 Days Sales Outstanding is 27.73 as of Jun. 2026, which is 28% below its 10-year median of 38.49. GuruFocus rates PRPO with a GF Score™ of 51/100 and a GF Value™ of $10.60 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 201 Medical Diagnostics & Research companies, Precipio ranks better than 91.54% on this metric.
Precipio's average Accounts Receivable for the
three
months ended in Jun. 2026 was $2.13 Mil. Precipio's Revenue for the
three
months ended in Jun. 2026 was $7.02 Mil.
Hence, Precipio's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 27.73.
The historical rank and industry rank for Precipio's Days Sales Outstanding or its related term are showing as below:
PRPO'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 20.68 Med: 38.49 Max: 118.42
Current: 26.02
During the past 13 years, Precipio's highest Days Sales Outstanding was 118.42. The lowest was 20.68. And the median was 38.49.
PRPO's Days Sales Outstanding is ranked better than 91.54% of 201
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.79
vs PRPO: 26.02
Precipio's Days Sales Outstanding
increased
from Jun. 2025 (19.88) to Jun. 2026 (27.73).
Precipio (NAS:PRPO) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Precipio Days Sales Outstanding Related Terms
Precipio Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Precipio's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRPO vs IDXG, ADVB, BIOQ: Days Sales Outstanding Comparison
For the Diagnostics & Research subindustry, Precipio's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Precipio Days Sales Outstanding vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Precipio's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Precipio's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Precipio (PRPO) has a Days Sales Outstanding of 27.73 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Precipio and its competitors. This is 28% below median its historical median of 38.49. Over the past decade, Precipio's Days Sales Outstanding has ranged from 20.68 to 118.42. According to the industry distribution chart, Precipio ranks #17 out of 201 companies in the Medical Diagnostics & Research industry, placing it in the top 8.5%.
Is Precipio's Days Sales Outstanding too high?
Precipio's current Days Sales Outstanding of 27.73 is 28% below median its 10-year median of 38.49. Over the past 10 years, this metric has ranged from a low of 20.68 to a high of 118.42. The Medical Diagnostics & Research industry median Days Sales Outstanding is 67.79. Precipio's value of 27.73 is 59.1% below this industry median. Based on the distribution chart, Precipio ranks #17 out of 201 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Precipio has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Precipio's Days Sales Outstanding compare to IDXG and ADVB?
According to the Medical Diagnostics & Research industry distribution chart, Precipio ranks #17 out of 201 companies for Days Sales Outstanding. This places Precipio in the top 9% of its industry — outperforming the majority of peers. The industry median Days Sales Outstanding is 67.79. Precipio's value of 27.73 is 59.1% below this benchmark. Historically, Precipio's own Days Sales Outstanding has ranged from 20.68 to 118.42 over the past decade. While the company's 10-year median is 38.49 vs. the industry median of 67.79, Precipio has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Diagnostics & Research company?
The median Days Sales Outstanding among Medical Diagnostics & Research companies is 67.79, based on 201 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Precipio's current Days Sales Outstanding of 27.73 is 59.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Precipio and its competitors. For the Medical Diagnostics & Research industry, the median Days Sales Outstanding is 67.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Precipio's current Days Sales Outstanding is 27.73, which is 28% below median its own 10-year median of 38.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Precipio stock overvalued right now?
Based on GuruFocus' analysis, Precipio (PRPO) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.60, compared to a current price of $30.29 — trading 185.8% above its estimated fair value. The current Days Sales Outstanding is 27.73, which is 28% below median its 10-year median of 38.49 and 59.1% below the Medical Diagnostics & Research industry median of 67.79. Precipio's overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Precipio (PRPO), the current Days Sales Outstanding is 27.73 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Precipio (PRPO) Overvalued in 2026?
Based on GuruFocus' analysis, Precipio stock appears to be overvalued.
The current stock price of $30.29 is trading 185.8% above its estimated GF Value™ of $10.60.
GuruFocus considers Precipio to be Significantly Overvalued.
Key valuation signals for PRPO:
Days Sales Outstanding: 27.73 (28% below median its 10-year median of 38.49)
GF Value™: $10.60 vs. price of $30.29 (185.8% above fair value)
Industry Position: 59.1% below the Medical Diagnostics & Research median (#17 of 201)
No single metric tells the full story. See the PRPO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.
51GF Score
Get the complete analysis for PRPO
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRPO has been successfully added to your 
